Home
August 2008 September 2008 October 2008
Su Mo Tu We Th Fr Sa
Week 36 1 2 3 4 5 6
Week 37 7 8 9 10 11 12 13
Week 38 14 15 16 17 18 19 20
Week 39 21 22 23 24 25 26 27
Week 40 28 29 30

Cryoablative Response of Prostate Cancer Cells is Influenced by Androgen Receptor Expression - Abstract Show Comments PDF Print E-mail
  
Monday, 25 February 2008

Institute of Biomedical Technology, SUNY, Binghamton, NY, USA.

To investigate in prostate cancer cells the consequences of androgen-insensitivity (AI) development on the cellular and molecular responses to freezing, as a challenge in prostate cancer treatment occurs when the androgen-sensitive (AS) phenotype switches to an AI phenotype, the latter of which is often refractory to many therapies.

PC-3 (AI) and LNCaP (AS) were each genetically altered to express the opposite phenotype and subjected to an in vitro freezing model. Viability, caspase inhibitor and Western blot studies were used to determine the basis of the differential responses of AI and AS cells.

LNCaP high-passage cells, formed by repeated passage of LNCaP (AS) cells, were AI and showed a phenotypic shift to freeze resistance matching the freeze response of PC-3 cells (AI). While stably transfected androgen receptor (AR)-transfected cells (PC-3 AR) had a freezing sensitivity similar to that of the LNCaP (AS) cell line. Importantly, AI cell lines survived and recovered from freezing exposure to temperatures as low as -40 degrees C whereas AS cell lines did not. Caspase inhibition studies and related fluorescent probes showed an elevated level of apoptotic involvement in both AS cell lines after freezing compared with their AI counterparts. Western blot analysis showed that AR expression was modified after exposure to freezing.

This study suggests that AS cancers may be far more sensitive to a freezing insult and this might be linked to elevated apoptosis and caspase activity. As such, cryoablation may prove most effective in cancer cells that have not yet progressed to a more resistant AI phenotype, but both generic variants can be fully ablated at sufficiently low temperatures.

Written by
Klossner DP, Baust JM, Vanbuskirk RG, Gage AA, Baust JG.

Reference
BJU Int. 2008 Feb 5. Epub ahead of print.

PubMed Abstract
PMID:18261151

UroToday.com Prostate Cancer Section

Reader Comments

Please log-in or register in order to submit comments.

Powered by AkoComment!

 
User Rating: / 2
PoorBest


 
Visitor Ratings:
Healthcare Professionals:
4 (1 votes)

No Affiliation:
5 (1 votes)